API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Submission of an IND application to U.S. FDA in support of the planned initiation of Phase I clinical study for its anti-CTLA4 antibody, UGN-301 (zalifrelimab), investigational immunotherapy designed for monotherapy and combination therapy in treating low-grade and high-grade disease.
Lead Product(s): Zalifrelimab,Imiquimod
Therapeutic Area: Oncology Product Name: UGN-301
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
Clinical trial of immunomodulators combining Imiquimod and Hydroxychloroquine to prevent and treat early COVID-19 infection.
Lead Product(s): Imiquimod,Hydroxychloroquine Sulphate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020